Pneumonia caused by severe acute respiratory syndrome coronavirus 2 emerged in China at the end of 2019. Because of the severe immunomodulation and lymphocyte depletion caused by this virus and the subsequent administration of drugs directed at the immune system, we anticipated that patients might experience fungal superinfection. We collected data from 186 patients who had coronavirus disease-associated pulmonary aspergillosis (CAPA) worldwide during March-August 2020. Overall, 182 patients were admitted to the intensive care unit (ICU), including 180 with acute respiratory distress syndrome and 175 who received mechanical ventilation. CAPA was diagnosed a median of 10 days after coronavirus disease diagnosis. Aspergillus fumigatus was identifi ed in 80.3% of patient cultures, 4 of which were azole-resistant. Most (52.7%) patients received voriconazole. In total, 52.2% of patients died; of the deaths, 33.0% were attributed to CAPA. We found that the cumulative incidence of CAPA in the ICU ranged from 1.0% to 39.1%.

COVID-19-associated pulmonary aspergillosis, March-August 2020 / J. Salmanton-Garcia, R. Sprute, J. Stemler, M. Bartoletti, D. Dupont, M. Valerio, C. Garcia-Vidal, I. Falces-Romero, M. Machado, S. de la Villa, M. Schroeder, I. Hoyo, F. Hanses, K. Ferreira-Paim, D.R. Giacobbe, J.F. Meis, J.-. Gangneux, A. Rodriguez-Guardado, S. Antinori, E. Sal, X. Malaj, D. Seidel, O.A. Cornely, P. Koehler. - In: EMERGING INFECTIOUS DISEASES. - ISSN 1080-6040. - 27:4(2021), pp. 1077-1086. [10.3201/eid2704.204895]

COVID-19-associated pulmonary aspergillosis, March-August 2020

S. Antinori;
2021

Abstract

Pneumonia caused by severe acute respiratory syndrome coronavirus 2 emerged in China at the end of 2019. Because of the severe immunomodulation and lymphocyte depletion caused by this virus and the subsequent administration of drugs directed at the immune system, we anticipated that patients might experience fungal superinfection. We collected data from 186 patients who had coronavirus disease-associated pulmonary aspergillosis (CAPA) worldwide during March-August 2020. Overall, 182 patients were admitted to the intensive care unit (ICU), including 180 with acute respiratory distress syndrome and 175 who received mechanical ventilation. CAPA was diagnosed a median of 10 days after coronavirus disease diagnosis. Aspergillus fumigatus was identifi ed in 80.3% of patient cultures, 4 of which were azole-resistant. Most (52.7%) patients received voriconazole. In total, 52.2% of patients died; of the deaths, 33.0% were attributed to CAPA. We found that the cumulative incidence of CAPA in the ICU ranged from 1.0% to 39.1%.
Aspergillus; COVID-19; SARS-CoV-2; aspergillosis; coronavirus disease; coronaviruses; fungi; intensive care unit; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; voriconazole; zoonoses; Aged; Antifungal Agents; Aspergillus fumigatus; Female; Humans; Immunologic Factors; Incidence; Intensive Care Units; International Cooperation; Male; Outcome and Process Assessment, Health Care; Registries; Respiration, Artificial; Risk Factors; SARS-CoV-2; Voriconazole; COVID-19; Pulmonary Aspergillosis
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
20-4895.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.51 MB
Formato Adobe PDF
1.51 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/867435
Citazioni
  • ???jsp.display-item.citation.pmc??? 68
  • Scopus 91
  • ???jsp.display-item.citation.isi??? 99
social impact